Generics 5

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Gliclazide manufacturers

5 products found

Filters

Filters

Filters , active

Country of origin : Vietnam

Clear all

5 products found

gliclazide

Tablets 30 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Vietnam
GMP approvals
PICS
Manufacturer #21831
Please provide me with the company information so I can write a short description for you. I need details about their products, licenses, competitive advantages, experience, track record, key regions, production lines (prescription medications, over-the-counter drugs, medical devices, supplements), therapy areas, dosage forms, GMP certifications, and product patents.

Manufacturer usually replies in 1 days

gliclazide

Tablets 30 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Vietnam
GMP approvals
WHO
Manufacturer #21654
This company is a pharmaceutical manufacturer specializing in a range of dosage forms, including tablets (conventional, modified-release, and extended-release) and capsules. They hold GMP certifications aligned with World Health Organization standards, ensuring high-quality production practices. Their key therapy areas are not specified in the provided information. The company's products are likely distributed across multiple regions, given their mention of "international" partners and online presence. While specific details about product patents and licenses are absent, the emphasis on GMP compliance suggests a commitment to regulatory standards.

gliclazide

Tablets 30 mg, 80 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Vietnam
GMP approvals
WHO
Manufacturer #21300
This pharmaceutical company, established in 2004, is a leader in research and development of prescription medications adhering to European quality standards. Focusing on affordability, they utilize around 80 active ingredients to produce drugs across four key therapy areas: cardiovascular, nervous system, diabetes, and dyslipidemia. Their R&D department, equipped with German technology and staffed by specialists, has successfully developed prolonged-release and micronized dosage forms.They primarily operate in Vietnam but also export to Cambodia, Indonesia, Singapore, and other regions.

Want to see all 5 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

GLICLAZIDE

Gliclazide is an anti-diabetic medication for the treatment of diabetes mellitus type 2. Gliclazide controls hyperglycemia in gliclazide-responsive diabetes mellitus of stable, mild, non-ketosis prone, type 2 diabetes. As an oral antihyperglycemic agent, it is used for the treatment of non-insulin-dependent diabetes mellitus. It has been classified differently according to its drug properties based on its chemical structure. When launched it belonged to the first-generation of sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one aromatic group. However, further studies have shown that Gliclazide is a second-generation sulfonylurea, because it has higher potency and a shorter half-life. Gliclazide is sold under the brand names Diamicron, Diaprel, Azukon, and others. Gliclazide was first patented in 1966 and approved for medical use in 1972. Due to its efficacy and use around the world, it has been listed on the World Health Organization's List of Essential Medicines. Gliclazide is not available for sale in the United States.

Forms and dose:

Gliclazide is available as a tablet and extended-release tablet. In the treatment of type 2 diabetes, the total daily dose recommended varies from 40-320mg. The dose is increased or decreased depending on the response to the therapy. The initial adult dose starts with 40-80mg daily. This can be increased until adequate control is reached. Please note that any single dose should not exceed 160mg. if a patient feels that they need higher doses, it is recommended to take medicine twice a day instead.

The price of Gliclazide:

In India, the lowest price consumers can pay for an 80 mg pill is $0.33. The same supply can cost as low as USD64 for the same supply for medicine.

How does it work?

Gliclazide is in the sulfonylurea family of medications. Its actions increase the release of insulin. It binds to the β cell sulfonylurea receptor subsequently blocking the ATP sensitive potassium channels. The process leads to the closing of channels that leads to a resulting decrease in potassium efflux. This eventually leads to depolarization of the β cells. In the next step, it opens voltage-dependent calcium channels in the β cell resulting in activation of calmodulin. The result of this process is exocytosis of insulin-containing secretory granules.

Finding Gliclazide Manufacturers and Suppliers

The best way to find and gain access to Gliclazide manufacturers and Gliclazide suppliers is to use Pipelinepharma's global B2B online marketplace for medicines and other pharmaceuticals. Normally, finding trusted manufacturers and supplies of specific drugs like Gliclazide can be a time-consuming challenge, but with Pipelinepharma's simple search engine and network of proven partners, the whole process becomes a lot easier. All you need to do to get started is to make use of our integrated search engine and start looking for suppliers or manufacturers of Gliclazide to work with. You can fine-tune your search results using various filters too, letting you search for Gliclazide from specific countries, for example.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation